Find a Research Expert

Experts
 Menu

Raymond L Stallings

Institution

Royal College of Surgeons in Ireland

Contact

Subjects

Biochemistry

Details
Publications 59
As first author 2
As last author 29
Unique topics 396
Collaborations 49
Sources 5
Are you Raymond L Stallings? Click here to provide feedback on your profile.
All
2017
2016
2015
2014
2013
2012
2011
2010
2009
All
2017
2016
2015
2014
2013
2012
2011
2010
2009

2017

A physiologically relevant 3D collagen-based scaffold-neuroblastoma cell system exhibits chemosensitivity similar to orthotopic xenograft models.
2017

MicroRNA-302d targets IRF9 to regulate the IFN-induced gene expression in SLE.
2016

Assessment of Basic Biological Functions Exerted by miRNAs.
2016

Endoplasmic reticulum stress-mediated upregulation of miR-29a enhances sensitivity to neuronal apoptosis.
2015

ER Stress-Mediated Upregulation of miR-29a Enhances Sensitivity to Neuronal Apoptosis.
2015

MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes.
2015

The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro.
2014

CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients.
2014

Differential DNA methylation profiles of coding and non-coding genes define hippocampal sclerosis in human temporal lobe epilepsy.
2014

Increased frequencies of the killer immunoglobulin-like receptor genes KIR2DL2 and KIR2DS2 are associated with neuroblastoma.
2013

Discovery and visualization of miRNA-mRNA functional modules within integrated data using bicluster analysis.
2013

ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours.
2013

Expressional alterations in functional ultra-conserved non-coding rnas in response to all-trans retinoic acid - induced differentiation in neuroblastoma cells.
2013

Investigating gene promoter methylation in a mouse model of status epilepticus.
2013

Metastasis suppressor microRNA-335 targets the formin family of actin nucleators.
2013

MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1.
2013

Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f.
2013

New Insights into the Genetics of Neuroblastoma : Implications for Diagnosis and Therapy.
2013

Orchestrating osteogenic differentiation of mesenchymal stem cells - identification of placental growth factor as a mechanosensitive gene with a pro-osteogenic role.
2013

The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.
2012

Differential DNA methylation patterns define status epilepticus and epileptic tolerance.
2012

Differential DNA methylation patterns define status epilepticus and epileptic tolerance.
2012

Expression profiling the microRNA response to epileptic preconditioning identifies miR-184 as a modulator of seizure-induced neuronal death.
2012

Expressional alterations in functional ultra-conserved non-coding RNAs in response to all-trans retinoic acid--induced differentiation in neuroblastoma cells.
2012

Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.
2012

Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles.
2012

MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway.
2012

MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome.
2012

MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1.
2012

Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs.
2012

Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase a oncogene.
2012

Reduced mature microRNA levels in association with dicer loss in human temporal lobe epilepsy with hippocampal sclerosis.
2012

The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.
2011

A 6-gene signature identifies four molecular subgroups of neuroblastoma.
2011

Co-localization of the oncogenic transcription factor MYCN and the DNA methyl binding protein MeCP2 at genomic sites in neuroblastoma.
2011

Loss of chromosome 1p/19q in oligodendroglial tumors: refinement of chromosomal critical regions and evaluation of internexin immunostaining as a surrogate marker.
2011

MicroRNA and DNA methylation alterations mediating retinoic acid induced neuroblastoma cell differentiation.
2011

MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma.
2011

MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2.
2011

Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene.
2011

Reduced mature microRNA levels in association with dicer loss in human temporal lobe epilepsy with hippocampal sclerosis.
2011

Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects.
2011

miRNA Expression profile after status epilepticus and hippocampal neuroprotection by targeting miR-132.
2011

miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs.
2010

Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma.
2010

Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.
2010

Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions.
2010

MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2.
2010

MicroRNA-184-mediated inhibition of tumour growth in an orthotopic murine model of neuroblastoma.
2010

MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma.
2010

MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma.
2010

Therapeutic targeting of miRNAs in neuroblastoma.
2010

miR-126 Is Downregulated in Cystic Fibrosis Airway Epithelial Cells and Regulates TOM1 Expression.
2010

miR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression.
2009

Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation.
2009

Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation.
2009

MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2.
2009

Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival.
2009

Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival.

These arethe5 unique sources for Raymond L Stallings's 59 publications. A single publication may appear in multiple sources. Click on a name or publication count to see the publications for a particular source.

Source #
Ireland -> Dublin City University 1
Ireland -> Dublin City University -> PubMed 1
Ireland -> Royal College of Surgeons in Ireland 58
Ireland -> Royal College of Surgeons in Ireland -> PubMed 43
Ireland -> Trinity College Dublin 1

  1. Further insights

    Clicking through these tabs will give you a wealth of further insights into this expert through their commonly used topics, the evolution of their expertise, their collaborators and their publications.

  2. Details

    Here is a quick breakdown of this expert's publication history

  3. Contact

    If this is the expert you have been looking for, simply click here to make contact.